We are experiencing the equivalent of the pre-Internet 1980s in health care—innovation is slow, expensive, and out of reach for most organizations. But new platforms revolutionizing medical innovation are emerging.
An unchecked collapse in biotechnology would be a disaster for the U.S. A meltdown would halt development of life-saving medicines, derail promising science, wipe out high-paying jobs, and weaken one of the pillars of America's high-tech future. But there are ways to turn the industry around.
"All of a sudden, biotechnology is not just what's medically necessary, but it's what can inspire us," says Reshma Shetty, cofounder of Boston-based startup Ginkgo BioWorks. And we must evolve how we view the science's purpose and participants.
While Washington spends yet another day failing to reform health care, New York is hosting 250 companies that are actively pushing the envelope in the pharmaceutical, medical, and biotech fields. The UBS Global Life Sciences Conference is one of the largest investor conferences in the world devoted to health care, and in its eleventh year it aims to connect investment dollars with innovators, breathing life into medical technologies that otherwise might die waiting for a cash infusion.